<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00505063</url>
  </required_header>
  <id_info>
    <org_study_id>07-088</org_study_id>
    <nct_id>NCT00505063</nct_id>
  </id_info>
  <brief_title>Prospective Trial of Vaccine Responses in Childhood Cancer Survivors</brief_title>
  <official_title>Phase II Prospective Trial of Vaccine Responses in Childhood Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      This study will look at your body's response to the new immunizations. We want to see how&#xD;
      well they will protect you. Immunization is the same as vaccination. Our goal is to protect&#xD;
      you as much as we can. We do not want you to have the measles, mumps, or whooping cough. We&#xD;
      are doing the study because there is no standard way to re-immunize people after cancer&#xD;
      treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To prospectively determine the response rate and duration of protective titers following revaccination with routine childhood immunizations in pediatric survivors of childhood cancer.</measure>
    <time_frame>conclusion of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine whether in vitro parameters of lymphoid reconstitution correlate with response and duration of response.</measure>
    <time_frame>conclusion of study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Childhood Cancer</condition>
  <condition>Multiple Diseases</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Immunization Schedule patients &lt;7 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Immunization Schedule patients &gt; or = to 7 years and &lt;11 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Immunization Schedule patients &gt; or = to 11 years of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunization Schedule patients &lt;7 years.</intervention_name>
    <description>Time 0 months: Prevnar 13 #1, Hib #1&#xD;
Time 1 months: Pediarix #1&#xD;
Time 2 months: Prevnar 13 #2, Hib #2&#xD;
Time 3-4 months: Pediarix #2&#xD;
Time 4-6 months: Draw post vaccine titers&#xD;
Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>vaccine, Prevnar 13</other_name>
    <other_name>vaccine, Menactra II</other_name>
    <other_name>Measles, mumps, rubella, MMR</other_name>
    <other_name>Live, attenuated varicella vaccine, Varivax</other_name>
    <other_name>Quadrivalent HPV Recombinant Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunization Schedule patients &gt; or = to 7 years and &lt;11 years of age</intervention_name>
    <description>Time 0 months: Hib #1, Prevnar 13 #1, Hepatitis B #1&#xD;
Time 1 month: Td#1, IPV #1(inactivated polio virus vaccine), Hepatitis B #2&#xD;
Time 2-3 months: Prevnar 13 #2, Hib #2&#xD;
Time 3-6 months: Td #2, Draw post vaccine titers Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>vaccine, Prevnar 13</other_name>
    <other_name>vaccine, Menactra II</other_name>
    <other_name>Measles, mumps, rubella, MMR</other_name>
    <other_name>Live, attenuated varicella vaccine, Varivax</other_name>
    <other_name>Quadrivalent HPV Recombinant Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunization Schedule patients &gt; or = to 11 years of age</intervention_name>
    <description>Time 0 month: Hib#1, Prevnar 13#1, Hepatitis B #1&#xD;
Time 1 month: Tdap(BOOSTRIX), Hepatitis B #2&#xD;
Time 2-3 months: Hib #2, Prevnar 13#2, Menactra&#xD;
Time 3-6 months: IPV, Draw post vaccine titers&#xD;
Time 6-12 months: Gardasil (dose #2 given 2 months after first dose, and dose #3 given 6 months after first dose)</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be &lt; or less 18 years of age at cancer diagnosis&#xD;
&#xD;
          -  Patient must be 3 to 24months following completion of chemotherapy for malignant&#xD;
             disease.&#xD;
&#xD;
               1. For patients &lt;12 months following completion of therapy, CR must be documented&#xD;
                  within 3 months of enrollment.&#xD;
&#xD;
               2. For patients &gt;12 months, CR must be documented at approximately 12 months and&#xD;
                  then only as clinically indicated&#xD;
&#xD;
             i. For patients with leukemia: bone marrow aspirate defined as &lt;5% blasts, absence of&#xD;
             cytogenetic abnormality by FISH or karyotype (if applicable) and no evidence of CSF&#xD;
             involvement (if applicable) ii. For patients with solid tumors remission will be&#xD;
             determined by appropriate radiologic scans, and other tests, including bone marrow&#xD;
             aspirate and biopsies demonstrating absence of extrinsic cells and absence of specific&#xD;
             FISH or cytogenetic abnormality (if applicable), iii. For patients with lymphoma,&#xD;
             remission will be determined by bone marrow aspirate and biopsy, radiologic scans and&#xD;
             other tests. Bone marrow will show &lt;5% blasts, absence of cytogenetic abnormality by&#xD;
             FISH or karyotype (if applicable), and flow cytometry (if lymphoma specific marker&#xD;
             present) and absence of CNS disease by spinal fluid (if applicable)&#xD;
&#xD;
          -  Patient may be of either gender and of any ethnic background&#xD;
&#xD;
          -  Patients or their guardians must be able to understand the nature and risk of the&#xD;
             proposed study and be able to sign consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Karnofsky score &lt;70%.&#xD;
&#xD;
          -  Female patients who are pregnant or lactating.&#xD;
&#xD;
          -  Patients who have received an autologous or allogeneic HCT.&#xD;
&#xD;
          -  Active uncontrolled bacterial or fungal infection.&#xD;
&#xD;
          -  Patients who have a history of previous allergic reaction to vaccinations currently&#xD;
             recommended by the ACIP.&#xD;
&#xD;
          -  Patients on any immunosuppressive drugs.&#xD;
&#xD;
          -  HIV-1,2 sero-positive patients.&#xD;
&#xD;
          -  Patients or guardians not signing informed consent.&#xD;
&#xD;
          -  Patients with prior allergic reaction to any vaccine component or to latex.&#xD;
&#xD;
          -  Patients who have received Rituximab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Kernan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center 1275 York Avenue</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 18, 2007</study_first_submitted>
  <study_first_submitted_qc>July 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>childhood</keyword>
  <keyword>cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

